Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54e65afc3bec220980be2a4ced7dca4b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 |
filingDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87b26b5e2973cc3b8c24d0e5978f5e09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11d8b2c57e7e0b810837218bc4f75e28 |
publicationDate |
2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3624793-A1 |
titleOfInvention |
Inhibition of gamma-glutamyltransferase and glutathione catabolism to enhance the efficacy of nf-kb signalling pathway inhibitors |
abstract |
The present invention relates to compositions for the treatment of a malignant disease and in particular to compositions comprising an NF-κB inhibitor and a γ-glutamyltransferase (γ-GT) inhibitor and therapeutic uses thereof. The invention further relates to in vitromethods of testing putative anti-tumour agents for their potential to act as therapeutically effective anti- tumour agents in vivo. Embodiments of the invention have been particularly developed for bringing NF-κB inhibitors to the clinic such asto provide alternative therapeutic options in the treatment of malignant diseases and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use. |
priorityDate |
2017-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |